Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253182841> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4253182841 abstract "Anti-fibrotic properties of ranibizumab have been well documented. As an antagonist to Vascular Endothelial Growth Factor (VEGF), ranibizumab works by binding and neutralizes all active VEGF, thus limits the progressive cell growth and proliferation. Its application in ocular diseases has shown remarkable desired effects, however to date its anti-fibrotic mechanism is not well understood. In this study, we identified metabolic changes in ranibizumab-treated Human Tenos’s fibroblast (HTF). Cultured HTFs were treated for48 hours with 0.5 mg/ml of ranibizumab and 0.5 mg/ml control IgG antibody which serves as a negative control. Samples from each group were injected into Agilent 6520 Q-TOF Liquid Chromatography/ Mass Spectrometer (LC/MS) System to establish the metabolite expression in both ranibizumab treated cells and control group. Data obtained was analysed using Agilent Mass Hunter Qualitative Analysis software to identify the most regulated metabolite following ranibizumab treatment. At statistical analysis of p -value < 0.01 with the cut off value of two-fold change, 31 identified metabolites were found to be significantly up-regulated in ranibizumab-treated group, with 6 of the mostly up-regulated have insignificant role in fibroblast’s cell cycle and wound healing regulations Meanwhile, 121 identified metabolites were down-regulated with seven of the mostly down-regulated are significantly involved in cell cycle and proliferation. Our findings demonstrated that ranibizumab abrogates the tissue scarring process and wound healing formation by regulating the expression of metabolites associated with fibrotic activity. In particular, we found that vitamin Bs are important in maintaining normal folic acid cycle, nucleotide synthesis, homocysteine and spermidine metabolism. This study provides an insight of ranibizumab mechanism of actions on HTFs from the perspective of metabolomics." @default.
- W4253182841 created "2022-05-12" @default.
- W4253182841 creator A5024554869 @default.
- W4253182841 creator A5034347521 @default.
- W4253182841 creator A5049767609 @default.
- W4253182841 date "2019-01-17" @default.
- W4253182841 modified "2023-10-17" @default.
- W4253182841 title "Important metabolites in maintaining folic acid, homocysteine and polyamine metabolism associated with ranibizumab treatment in cultured Human Tenon’s Fibroblast" @default.
- W4253182841 doi "https://doi.org/10.7287/peerj.preprints.27492" @default.
- W4253182841 hasPublicationYear "2019" @default.
- W4253182841 type Work @default.
- W4253182841 citedByCount "0" @default.
- W4253182841 crossrefType "posted-content" @default.
- W4253182841 hasAuthorship W4253182841A5024554869 @default.
- W4253182841 hasAuthorship W4253182841A5034347521 @default.
- W4253182841 hasAuthorship W4253182841A5049767609 @default.
- W4253182841 hasBestOaLocation W42531828411 @default.
- W4253182841 hasConcept C126322002 @default.
- W4253182841 hasConcept C185592680 @default.
- W4253182841 hasConcept C202751555 @default.
- W4253182841 hasConcept C203014093 @default.
- W4253182841 hasConcept C2776694085 @default.
- W4253182841 hasConcept C2777477808 @default.
- W4253182841 hasConcept C2777802072 @default.
- W4253182841 hasConcept C2780269544 @default.
- W4253182841 hasConcept C2780381497 @default.
- W4253182841 hasConcept C2781100027 @default.
- W4253182841 hasConcept C55493867 @default.
- W4253182841 hasConcept C62112901 @default.
- W4253182841 hasConcept C71924100 @default.
- W4253182841 hasConcept C98274493 @default.
- W4253182841 hasConceptScore W4253182841C126322002 @default.
- W4253182841 hasConceptScore W4253182841C185592680 @default.
- W4253182841 hasConceptScore W4253182841C202751555 @default.
- W4253182841 hasConceptScore W4253182841C203014093 @default.
- W4253182841 hasConceptScore W4253182841C2776694085 @default.
- W4253182841 hasConceptScore W4253182841C2777477808 @default.
- W4253182841 hasConceptScore W4253182841C2777802072 @default.
- W4253182841 hasConceptScore W4253182841C2780269544 @default.
- W4253182841 hasConceptScore W4253182841C2780381497 @default.
- W4253182841 hasConceptScore W4253182841C2781100027 @default.
- W4253182841 hasConceptScore W4253182841C55493867 @default.
- W4253182841 hasConceptScore W4253182841C62112901 @default.
- W4253182841 hasConceptScore W4253182841C71924100 @default.
- W4253182841 hasConceptScore W4253182841C98274493 @default.
- W4253182841 hasLocation W42531828411 @default.
- W4253182841 hasOpenAccess W4253182841 @default.
- W4253182841 hasPrimaryLocation W42531828411 @default.
- W4253182841 hasRelatedWork W1663066078 @default.
- W4253182841 hasRelatedWork W2092115751 @default.
- W4253182841 hasRelatedWork W2114382514 @default.
- W4253182841 hasRelatedWork W2352908745 @default.
- W4253182841 hasRelatedWork W2365737025 @default.
- W4253182841 hasRelatedWork W2789283976 @default.
- W4253182841 hasRelatedWork W2899084033 @default.
- W4253182841 hasRelatedWork W3174847431 @default.
- W4253182841 hasRelatedWork W4253182841 @default.
- W4253182841 hasRelatedWork W51238803 @default.
- W4253182841 isParatext "false" @default.
- W4253182841 isRetracted "false" @default.
- W4253182841 workType "article" @default.